Page 32 – Nykode

Vaccibody AS announces approval to initiate its first clinical trial

Vaccibody AS is pleased to announce that it has received the approval from the regulatory authorities (Paul Ehrlich Institute), of […]

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, […]

Vaccibody AS is pleased to announce initiation of a new 4 year collaborative research project with the aim to […]

The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 Million through the Norwegian […]

Vaccibody AS, a biopharmaceutical company focusing on immunotherapy and vaccines, is pleased to announce the filing of a CTA to […]

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The […]

Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the […]

Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format […]

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a […]

Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. […]